


Oxprenolol hydrochloride

Cat. No.:	HY-B1486
CAS No.:	6452-73-9
Molecular Formula:	C ₁₅ H ₂₄ ClNO ₃
Molecular Weight:	301.81
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (828.34 mM; Need ultrasonic)					
	H ₂ O : 100 mg/mL (331.33 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		3.3133 mL	16.5667 mL	33.1334 mL
5 mM			0.6627 mL	3.3133 mL	6.6267 mL	
	10 mM		0.3313 mL	1.6567 mL	3.3133 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.89 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.89 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.89 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a K _i of 7.10 nM in a radioligand binding assay using rat heart muscle ^[1] .
IC₅₀ & Target	β-adrenoceptor 7.1 nM (K _i)
In Vitro	Oxprenolol is lipophilic ^[3] . ?Oxprenolol shows permeability rate constant of 1.54 ± 1.54×10 ⁻³ cm/h across abdominal human skin ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Oxprenolol (200 mg/kg/day; p.o.; daily for 3 weeks) produces effective beta-blockade^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male rats (230 to 300 g body wt) of the Wistar strain ^[2]
Dosage:	200 mg/kg
Administration:	Administered orally; daily for 3 weeks
Result:	This dosage produced effective beta-blockade.

CUSTOMER VALIDATION

- J Pharmaceut Biomed. 2020, 113870.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Modamio P, et al. A comparative in vitro study of percutaneous penetration of β -blockers in human skin. International journal of pharmaceutics, 2000, 194(2): 249-259.

[2]. T Nagatomo, et al. Binding Characteristics of ³H-dihydroalprenolol to Beta-Adrenoceptors of Rat Heart Treated With Neuraminidase. Jpn J Pharmacol. 1983 Aug;33(4):851-7.

[3]. A S Manning, et al. Abrupt Withdrawal of Chronic Beta-Blockade: Adaptive Changes in Cyclic AMP and Contractility. J Mol Cell Cardiol. 1981 Nov;13(11):999-1009.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA